Jain J, Samal B, Singhakowinta A, Vaitkevicius V K
Cancer. 1977 Nov;40(5):2063-6. doi: 10.1002/1097-0142(197711)40:5<2063::aid-cncr2820400511>3.0.co;2-w.
Antiestrogen compounds are relatively new in the treatment of breast cancer. A clinical trial of Nafoxidine therapy is being pursued in our institution. In a selected group of patients with metastatic breast cancer who had, in the past, undergone adrenalectomy, Nafoxidine therapy produced objective tumor regression in six out of ten patients. Of the six patients whose tumors contained demonstrable estrogen receptors, four showed regression (67%), one patient had stable disease, and one showed tumor progression. Of the four patients in whom estrogen receptor estimation was not done, two had, in the past, shown regression after endocrine therapy and they also showed regression of tumor with Nafoxidine therapy. In patients with metastatic breast carcinoma, who have undergone adrenalectomy in the past, a therapeutic trial with Nafoxidine may be worthwhile particularly in patients who have demonstrable estrogen receptor in the tumor of those who have in the past shown regression of tumor after endocrine therapy.
抗雌激素化合物在乳腺癌治疗中相对较新。我们机构正在进行一项萘福昔定治疗的临床试验。在一组选定的既往接受过肾上腺切除术的转移性乳腺癌患者中，萘福昔定治疗使十分之六的患者出现了客观的肿瘤消退。在肿瘤含有可检测到的雌激素受体的6名患者中，4名出现消退（67%），1名患者病情稳定，1名患者肿瘤进展。在4名未进行雌激素受体评估的患者中，2名既往在内分泌治疗后出现消退，他们在接受萘福昔定治疗后肿瘤也出现消退。在既往接受过肾上腺切除术的转移性乳腺癌患者中，进行萘福昔定治疗试验可能是值得的，特别是在肿瘤中有可检测到雌激素受体的患者或既往在内分泌治疗后肿瘤出现消退的患者中。
